Real World Evidence Lead Endo-Metabolic, Global Rare Diseases
Pubblicato il 12-08-2026 - Chiesi Farmaceutici in Parma
Real World Evidence Lead Endo-Metabolic, Global Rare Diseases
Faccia clic su "Candidati" qui sotto per inviare la sua candidatura. Si assicuri che il suo CV sia aggiornato e di aver prima letto le specifiche del lavoro.
Date: 22 Jul 2026
Department: GRD Global Medical Affairs
Business Area: Mktg, Market Access, Bus. Excellence & Med. Affair
Job Type: Direct Employee
Contract Type: Permanent
Location: Europe, IT
About us
Chiesi is an international research-focused biopharmaceutical group with 90 years’ experience, operating in more than 30 countries, with its Headquarter in Parma, Italy. More than 8,000 employees across the group are united by a singular purpose: promoting a healthier world for our people, patients, and the planet. This is what drives us as we research, develop, and market innovative drugs across our main therapeutic areas. Discover more here.
At Chiesi we are thinking generations ahead, driving sustainable innovation with purpose. This fosters a culture of reliability, transparency, and ethical behaviour at every level.
As a Agevolazioni Corporation and a certified B Corp, we have embedded sustainability in our bylaws and continuously measure our impact.
Diversity and inclusion are at the heart of who we are. We believe our differences make us stronger. We are a vibrant ecosystem of passionate, talented individuals united by strong values, each bringing unique perspectives that help us to continuously challenge the status quo for the better.
Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a Chiesi Group’s business unit established in February 2020 and focused on research, development and commercialization of treatments and patient support services for rare and ultra‑rare disorders, many of whom have limited or no treatments available.
This unit is based in Boston, Massachusetts, with a strong synergy with the headquarters in Parma.
Rare unit has a focus on research and product development for lysosomal storage diseases, rare hema